Navigation Links
Advanced Immune Support Formula Licensed From UC Berkeley Launched
Date:10/1/2007

BERKELEY, Calif., Oct. 1 /PRNewswire/ -- Berkeley BioSciences, Inc., co-founded by Dr. Leonard Bjeldanes, Professor and former Chairman of the Department of Nutritional Sciences at UC Berkeley and Dr. Gary Firestone, Director of the National Institutes of Health Cancer Research Program at UC Berkeley, announces the launch of ActivaMune -- an advanced immune support formula exclusively licensed from UC Berkeley. (http://www.ActivaMune.com/).

ActivaMune is based on a breakthrough discovery by Dr. Bjeldanes and Dr. Firestone regarding the potent immune activating properties of Diindolylmethane (DIM), a naturally occurring compound found in Brassica vegetables (broccoli, cauliflower, cabbage, kale, Brussels sprouts). This compound has been shown to modulate key immune enhancing cytokines in addition to inducing Interferon-Gamma Receptors on diseased cells, selectively marking them for destruction by the immune system with no effect on healthy cells.

DIM, at dietary supplemental dosages, is currently used as a treatment for Recurring Respiratory Papillomatosis tumors (caused by the Human Papillomavirus) and is in Phase III clinical trials for Cervical Dysplasia (also caused by HPV). Until this recent discovery regarding its potent immune modulating properties, the efficacy of this compound against these conditions was not clearly understood. As a result of this discovery, Diindolylmethane is currently under investigation as a natural therapeutic for most viral infections (including HPV, Influenza, Hepatitis & HIV) and antibiotic resistant bacteria. As DIM has both immune modulating properties that fight cancer, as well as direct anti-cancer properties (such as apoptosis promotion) it is also currently in clinical trials sponsored by the National Cancer Institute as a natural therapeutic for various forms of cancer.

Epidemiological studies have indicated that people who regularly consume Brassica vegetables have a significantly lower risk of cancer. Scientists believe that the three principal nutrients in Brassica vegetables responsible for these protective properties are: Diindolylmethane, Sulforaphane and Selenium. ActivaMune is the first dietary supplement in the market to deliver all three of these health promoting nutrients from Brassica vegetables in one capsule. Most Brassica extract pills on the market today do not contain any Diindolylmethane or Sulforaphane in them as the enzyme responsible for their production is destroyed during the manufacturing process. In addition to Brassica phytonutrients, ActivaMune also provides important nutrients from other vegetables as well to promote healthy aging.

Proceeds from ActivaMune sales support research and development of nature-based therapeutics for cancer, AIDS and other diseases.


'/>"/>
SOURCE Berkeley BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Achieving Reliable Protein Quantitation Results Using ICAT Reagents, MALDITOF Mass Spectrometry, and Advanced Data Interpretation Tool
2. Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option
3. 384 Well Pipetting Precision and Accuracy Testing Using the Sciclone Advanced Liquid Handler
4. WARF expands license agreement with Advanced Cell Technology
5. Rockwells $1M gift to UWM will support advanced automation research
6. Advanced CIO: Technology execs must trumpet their success
7. FDA approves advanced digital mammography system
8. Tech Digest: Inacom; St. Michaels, St. Clares hospitals; Merge eMed; Advanced Data-Comm; Blue Cross and Blue Shield
9. Wisconsins insurance companies use advanced IT to speed relief
10. $60 Million Available in Advanced Tech Competition
11. Advanced Life Sciences to Hit the Road For $30 Million in Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):